Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookie, but we will activate these services only with your consent. If you press the button “Accept”, you consent to the use of these analytics scripts.
You can withdraw your consent at any time. To do so, please modify your configurations on this website by following this link to our privacy statement with the configuration options:
Go to settings
A mix of strong entrepreneurial spirit, close collaboration and outstanding performance define our approach to leadership alongside a commitment to diversity and inclusivity.
2/12/2021
Aachen, Germany, 12 February 2021 – Grünenthal has announced the successful extension of its existing €535 million term loan bank facilities. This amendment was conducted in the broader context of the company’s acquisition of the European rights (excluding Spain and the UK) to the lipid-lowering medication CRESTOR™ completed in February 2021.
2/10/2021
Aachen, Germany, 10 February 2021 – Grünenthal today announced the successful completion of its acquisition of the European rights to CRESTOR™ (excluding Spain and the UK) for a total consideration of up to US$ 350 million.
1/12/2021
Aachen, Germany, 12 January 2021 – Florian Dieckmann became Vice President and Head Global Communications at Grünenthal on 1 January 2021. He succeeds Štěpán Kráčala, who transformed the research-driven pharmaceutical company’s Communications department from 2018 until the end of last year.
Fabia Kehren
Head External Communications and Editorial Management
Grünenthal GmbH
52099 Aachen
Phone +49 241 569-1616
E-Mail Fabia.Kehren@grunenthal.com